Reduced Recurrence of Prostate Cancer with Novel Autologous Cancer Vaccine (FK- PC101) Post-Prostatectomy: Long-Term Results from a Single-Center Phase 1/2 Study - Beyond the Abstract
Full Commentary: The management of high-risk prostate cancer following radical prostatectomy remains one of the most debated challenges in uro-oncology. Despite refinements in surgical technique and adjuvant therapies, nearly half of these patients experience biochemical recurrence (BCR) within three years. The FK002-2001 study, conducted at the Hospital de Clínicas de Porto Alegre (Brazil), introduces promising data on how immunotherapy could reshape this space.
This phase 1/2 single-center trial evaluated FK-PC101, an autologous, immunomodulated tumor-cell vaccine designed to stimulate patient-specific immune responses against tumor neoantigens. Sixty-two men with high-risk prostate cancer were retrospectively analyzed, including 23 who received the vaccine after radical prostatectomy. Notably, the vaccine group presented with more aggressive baseline disease—higher Gleason scores and advanced T stages—yet showed a significantly lower PSA recurrence rate at four years (11.8% vs 36.8%; p = 0.0453). All vaccinated patients completed the seven-dose intradermal regimen, and adverse events were mild and transient.
From a clinical standpoint, these findings suggest that autologous cancer vaccination may bridge the gap between surgery and systemic therapy, potentially delaying or preventing biochemical relapse. While the study’s non-randomized design limits definitive conclusions, the trend toward prolonged recurrence-free survival, despite worse baseline pathology, reinforces the biological rationale of the vaccine’s mechanism.
Unlike androgen deprivation therapy (ADT) or early salvage radiotherapy, which carry meaningful quality-of-life implications, an autologous vaccine provides a short, outpatient, low-toxicity, and cost-effective intervention that can be easily integrated into postoperative care. Importantly, the vaccine is produced using the patient’s own tumor tissue with a very cost-effective process, making the approach potentially affordable and scalable.
Beyond its numerical results, FK-PC101 represents an immunologic personalization of prostate cancer management. By leveraging each patient’s own tumor as an antigenic source, the vaccine induces a targeted immune response that complements existing surgical and systemic strategies. This same principle holds promise for other solid tumors, including bladder, colon, gastric, and pancreatic cancers, where tumor-derived antigens can serve as personalized immunogenic templates—potentially expanding the reach of this technology far beyond prostate cancer.
A randomized, multicenter phase 2 trial (NCT06636682) is now ongoing to evaluate FK-PC101 in a controlled setting. If confirmed, these findings could establish FK-PC101 as one of the first immunotherapeutic options for the adjuvant, non-metastatic prostate cancer population.
In summary, FK-PC101 demonstrates safety, feasibility, affordability, and a signal of reduced biochemical recurrence after radical prostatectomy in high-risk patients. These results support continued investigation of personalized, accessible cellular immunotherapy as a complementary strategy in the evolving landscape of prostate cancer—and potentially other solid tumors—offering an effective and economically viable path forward.
Written by: Fernando Thomé Kreutz, MD, PhD, Founder and CEO, CellVax Therapeutics Inc, USA, FK-Biotecnologia S/A Brazil, Porto Alegre, Brazil
Read the Abstract